🔗 Share this article WHO Raises Alert Over Acute Lack of Obesity Injections Under 10% of people eligible to benefit from GLP-1 drugs such as Wegovy can access them, warns the World Health Organization as it releases its initial guidance on the therapies. Given over a billion people worldwide now living with obesity, it is advocating for broader and more equitable access to these injectable treatments. Per estimates, over two billion could be obese by 2030 unless action is taken. "Our new guidelines acknowledges that excess weight is a chronic disease that can be treated with holistic and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and supply-chain constraints are major hurdles to universal availability to the jabs that can aid individuals in losing substantial body mass, notes the body. Skinny Jab Supply Crisis Even under the current most favorable scenario, the supply of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of eligible patients, per the WHO. The guideline encourages nations and manufacturers to increase access, via approaches such as patent sharing. The intellectual property rights on the active ingredient – the core component of the drug Wegovy – is scheduled to end in several nations in 2026. The Way Weight-Loss Injections Function These medications imitate a biological compound to reduce digestion speed, reduce hunger and enhance feelings of fullness so people consume fewer calories. People commonly see weight reduction in the initial weeks of starting on the weekly injections. Studies indicates users may put most of the weight back on a year later of discontinuing the drug, when their usual food cravings return. To be carrying excess weight elevates your risk for developing diseases, such as diabetes, cardiovascular issues, brain attack, and specific malignancies. Obesity impacts people in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
Under 10% of people eligible to benefit from GLP-1 drugs such as Wegovy can access them, warns the World Health Organization as it releases its initial guidance on the therapies. Given over a billion people worldwide now living with obesity, it is advocating for broader and more equitable access to these injectable treatments. Per estimates, over two billion could be obese by 2030 unless action is taken. "Our new guidelines acknowledges that excess weight is a chronic disease that can be treated with holistic and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and supply-chain constraints are major hurdles to universal availability to the jabs that can aid individuals in losing substantial body mass, notes the body. Skinny Jab Supply Crisis Even under the current most favorable scenario, the supply of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of eligible patients, per the WHO. The guideline encourages nations and manufacturers to increase access, via approaches such as patent sharing. The intellectual property rights on the active ingredient – the core component of the drug Wegovy – is scheduled to end in several nations in 2026. The Way Weight-Loss Injections Function These medications imitate a biological compound to reduce digestion speed, reduce hunger and enhance feelings of fullness so people consume fewer calories. People commonly see weight reduction in the initial weeks of starting on the weekly injections. Studies indicates users may put most of the weight back on a year later of discontinuing the drug, when their usual food cravings return. To be carrying excess weight elevates your risk for developing diseases, such as diabetes, cardiovascular issues, brain attack, and specific malignancies. Obesity impacts people in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.